Trending

#sdgr

Latest posts tagged with #sdgr on Bluesky

Latest Top
Trending

Posts tagged #sdgr

Post image Post image

#ドール用服 #ドレス
ブラック/ホワイト色
SDGR/SD16/68サイズ
2026年3月04日まで5%OFF!
#legenddoll 送料無料に参加可能です。
www.legenddoll.com/search?cate_...
#bjd #SDGR #SD16 #送料無料

3 0 0 0
Post image

#volks #sdgr #yumepi #volksdoll #bjd

Got new eyes for yumepi recently

2 0 0 0
Preview
Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities Schrödinger (Nasdaq: SDGR) summarized 2025 progress and laid out 2026 priorities to scale its physics+AI computational platform and expand drug discovery collaborations. Key 2025 milestones include strategic agreements with Lilly and Manas AI, a beta Predictive Toxicology solution covering ~50 kinases, 20 peer-reviewed publications, and initial Phase 1 clinical data for SGR-1505. Regulatory recognitions include Fast Track and Orphan Drug designations for SGR-1505 in Waldenström macroglobulinemia. 2026 priorities focus on platform scaling, completing Phase 1 data for SGR-1505 and SGR-3515, presenting SGR-3515 data H1 2026, and pursuing partnerships to advance clinical programs.

#SDGR Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

www.stocktitan.net/news/SDGR/schrodinger-pr...

0 0 0 0
Post image Post image

#ドール服 #新作情報
ヘップバーンスタイル
ブラック/ホワイト色
MSD/SDGR/SD/SD16/FL65/SD17/POPO68/69cmサイズ人形用あります😍👏
www.legenddoll.com/brand-252.html
#legenddoll #MSD #SDGR #SD16 #球体関節人形

4 0 0 0

Here's my list of who could win...

1.) Biotechnology - train scientific foundation models for biology to automate drug/material discovery

Potential winners: #RXRX #DNA #SDGR #ABSI #TWST #ADPT

0 0 1 0

#SDGR Schrödinger Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/SDGR/schrodinger-re...

0 0 0 0
Preview
Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger Copernic Catalysts and Schrödinger (SDGR) announced they have surpassed the final technical milestone for their jointly developed ammonia synthesis catalyst, Neptune. Neptune delivered an ammonia yield >2x that of competing catalysts under real-world reactor conditions and met the collaboration's success criteria.The release states Neptune could raise industrial plant capacity by up to 47%, add up to $110 million in annual plant-level profit, and cut energy use from the Haber-Bosch process by up to 23%. Copernic is scaling up with toll manufacturers and plans pilot-scale demonstrations in 2026/27, with commercial sales targeted after successful pilots. Copernic and Schrödinger have also begun joint work on a selective ethylene oxide catalyst.

#SDGR Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

www.stocktitan.net/news/SDGR/copernic-catal...

0 0 0 0
Post image Post image

ドール用服 #更新情報
ドレスセット【晨雾】✨
2025年11月7日13時まで期間限定受付中✨
ブルー/グリーンの2色あり、MSD/SD/SDGR/SD16/DZ70サイズ選択可能です✨
1万円以上、送料無料に参加出来ます!👏
詳細➡️プロフィールのリンクから入り、ドレスセットでご検索下さい。
#BJD #legenddoll #期間限定 #ドレス #MSD #SD #SDGR #SD16 #送料無料 #新作情報 #ドレス

5 0 0 0

AI biotech is starting to wake up:
- #QSI +16%
- #RXRX +15%
- #TWST +15%
- #SDGR +10%
- #TEM +8%

This is the last significantly undervalued + undiscovered corner of the AI Boom.

It’s also where you could find your next 10X AI winner…

0 0 0 0
Post image Post image Post image

勉強ひと休み📱 #bjd #sdgr #doll

24 4 0 0

#TEM has skyrocketed. But that's more healthcare AI. Lotta biotech AI names remain depressed, and that may be a set-up for a big move higher in some of these stocks #RXRX #ADPT #SDGR #NNOX #TWST

0 0 0 0
Post image Post image

ドール用服 #更新情報
✨レースパジャマ✨
グリーン/ネイビー/ブラック/ピンク/ホワイト/ライトパープル/ベージュ/グレー色
MSD/SDGR/SD/SD16/FL65/SD17/POPO68/69cmサイズあります😍
詳細➡️プロフィールのリンクから入り、パジャマでご検索下さい。
#bjd #パジャマ #レース #セクシー #MSD #SDGR #SD #SD16 #SD17 #POPO68 #legenddoll #ドール服

3 0 0 0
Post image Post image

#ドール用服 #更新情報
イブニングドレス
ホワイト/ブラック/ブルー/グレーブルー色
SDGR/SD/SD16/FL65/SD17/POPO68/69cmサイズ用あります✨
1万円以上、送料無料に参加出来ます!👏
詳細➡️プロフィールのリンクから入り、イブニングドレスでご検索下さい。
#bjd #SD #送料無料 #SDGR #legenddoll #ドレス

6 0 0 0
Post image Post image

Misako (Volks SDGr Macha) at #ANYC!
I met a couple doll fans, it was nice to chat! 💖

#animenyc #BJD #SDGr #volks #superdollfie #ボークス #スーパードルフィー

6 1 0 0

BREAKING NEWS: ( NASDAQ: #SDGR ) Neutral Recommendation Issued On SDGR By Citigroup

0 0 0 0
Preview
Biotech Schrödinger Discontinues Promising Leukemia Drug SGR-2921 Following Safety Concerns Two treatment-related deaths in Phase 1 trial lead to discontinuation of CDC7 inhibitor SGR-2921 for acute myeloid leukemia, despite early efficacy signals. Get details.

#SDGR Schrödinger Announces Discontinuation of SGR-2921 Program

www.stocktitan.net/news/SDGR/schrodinger-an...

0 0 0 0
Schrödinger Reports Second Quarter 2025 Financial Results Schrödinger (Nasdaq: SDGR) reported Q2 2025 financial results with total revenue of $54.8 million, up 16% year-over-year. Software revenue increased 15% to $40.5 million, while drug discovery revenue reached $14.2 million.The company presented encouraging Phase 1 data for its MALT1 inhibitor SGR-1505 in B-cell malignancies and received FDA Fast Track Designation for Waldenström macroglobulinemia treatment. Initial clinical data for two other programs, SGR-3515 and SGR-2921, is expected in Q4 2025.Schrödinger maintained its 2025 software revenue growth guidance of 10-15% and implemented cost-reduction measures, including a 7% workforce reduction expected to save approximately $30 million annually.

#SDGR Schrödinger Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/SDGR/schrodinger-re...

0 0 0 0
Preview
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target Schrödinger (NASDAQ:SDGR) and Ajax Therapeutics have expanded their exclusive research collaboration to include a new JAK target, building on their successful partnership established in 2019. The collaboration's lead candidate, AJ1-11095, a potential first-in-class Type II JAK2 inhibitor, is currently in Phase 1 clinical trials for myelofibrosis treatment.The expanded partnership aims to develop novel JAK inhibitors for both oncology and inflammatory/autoimmune disorders. Under the amended agreement, Ajax will lead clinical development and commercialization, while Schrödinger will receive milestone payments, single-digit royalties on net sales, and maintains its equity stake in Ajax following their participation in Ajax's $95 million Series C financing in 2024.

#SDGR Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

www.stocktitan.net/news/SDGR/ajax-therapeut...

0 0 0 0
Preview
FDA Fast Track: Schrödinger's SGR-1505 Targets Resistant Blood Cancer with Promising Phase 1 Data Novel MALT1 inhibitor shows promise for BTK-resistant blood cancer. Phase 1 data reveals favorable safety profile across multiple B-cell malignancies. Learn more.

#SDGR Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

www.stocktitan.net/news/SDGR/schrodinger-re...

0 0 0 0
Preview
Investor Alert: Pomerantz Law Firm Investigates Possible Securities Fraud at Schrödinger, Inc. Pomerantz Law Firm is probing into potential securities fraud involving Schrödinger, Inc., following significant stock price fluctuations. Investors should stay informed.

Investor Alert: Pomerantz Law Firm Investigates Possible Securities Fraud at Schrödinger, Inc. #USA #New_York #Pomerantz #Schrödinger #SDGR

0 0 0 0
Preview
Clinical Trial Success: New Drug SGR-1505 Shows 22% Response Rate in Hard-to-Treat Blood Cancers SGR-1505 achieves 22% response rate across various B-cell cancers, with strong results in CLL and Waldenström patients. See complete safety profile and efficacy data.

#SDGR Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

www.stocktitan.net/news/SDGR/schrodinger-re...

0 0 0 0
Based on the above discussion, Recursion Pharmaceuticals, with its innovative pipeline of candidates, encouraging collaboration agreement, narrowing loss estimates, and cheaper valuation, is a far better bargain for investors looking to invest in AI-powered drug discovery stocks with higher growth potential. RXRX is thus a clear-cut winner.

Based on the above discussion, Recursion Pharmaceuticals, with its innovative pipeline of candidates, encouraging collaboration agreement, narrowing loss estimates, and cheaper valuation, is a far better bargain for investors looking to invest in AI-powered drug discovery stocks with higher growth potential. RXRX is thus a clear-cut winner.

#Recursion #RXRX vs. #SDGR:

Which #AI - Powered Drug Discovery Stock Has More Upside?

www.tradingview.com/news/zacks:9...

1 0 0 0
Preview
Morgan Stanley Director Takes CFO Role at Schrödinger as Company Reaffirms 2025 Guidance Former Morgan Stanley MD Richie Jain succeeds Geoffrey Porges as CFO. Company maintains financial outlook amid leadership transition. See full details.

#SDGR Schrödinger Announces CFO Appointment

www.stocktitan.net/news/SDGR/schrodinger-an...

0 0 0 0
Post image

I am hosting a split for a Volks SDGr Ranma. Only the outfit is available to claim for $250! Looking for USA participant. It is the outfit, shoes, and wig. Payment not taken until doll arrives to me. Paypal ff only.

#bjdsplit #bjdsale #bjd #dollsky #volks #ranma #sdgr

3 0 1 0
Preview
Schrödinger Reports Strong First Quarter 2025 Financial Results Schrödinger (NASDAQ: SDGR) reported strong Q1 2025 financial results with total revenue of $59.6 million, up 63% year-over-year. Software revenue grew 46% to $48.8 million, while drug discovery revenue reached $10.7 million, up from $3.2 million in Q1 2024. Despite revenue growth, the company posted a net loss of $59.8 million. Software gross margin was 72%, down from 76% in Q1 2024. The company maintained its 2025 guidance, expecting software revenue growth of 10-15% and drug discovery revenue of $45-50 million. Schrödinger plans to present initial clinical data for its MALT1 inhibitor SGR-1505 in June and expects data from two other clinical trials in H2 2025. The company is also advancing its predictive toxicology initiative, expected to launch in H2 2025.

#SDGR Schrödinger Reports Strong First Quarter 2025 Financial Results

www.stocktitan.net/news/SDGR/schrodinger-re...

0 0 0 0
Preview
Schrödinger Reveals Breakthrough Cancer Drug Data: Two Novel Compounds Outperform Current Treatments New preclinical data shows enhanced efficacy for SGR-3515 and SGR-4174 in targeting aggressive cancers. Phase 1 trial results coming H2 2025. Get insights.

#SDGR Schrödinger Presents New Preclinical Data at AACR Annual Meeting

www.stocktitan.net/news/SDGR/schrodinger-pr...

0 0 0 0